BMI1 and ovarian cancer: BMI1 is a validated target of miR-200c (Cui et al., 2014), thus this suppression of BMI1 by miR-200c may therefore also suppresses ABC transporters levels and promotes the cisplatin sensitivity in ovarian cancer, however, further research is needed to address this relationship and how will it affects the survival outcomes of the ovarian cancer patients.